SGSH and mucopolysaccharidosis type 3A: A clinical trial of LYS-SAF302, an AAV-10 vector carrying the human N-sulfoglucosamine sulfohydrolase (SGSH) for Sanfilippo syndrome type A, was put on hold by the FDA in June 2020 following observations of localized findings on magnetic resonance imaging at the intracerebral injection sites (Table 2).